原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展

doi:10.3969/j.issn.1004-583X.2024.01.016

摘要/Abstract

摘要：

自身免疫性肝病主要包括自身免疫性肝炎(autoimmune hepatitis,AIH)、原发性胆汁性胆管炎(primary biliary cholangitis,PBC)、原发性硬化性胆管炎。临床上部分患者出现两种或两种以上自身免疫性肝病的临床、生化及病理特征,称为重叠综合征,其中PBC-AIH重叠综合征最常见。与独立诊断的PBC或AIH患者相比,PBC-AIH重叠综合征的肝脏相关不良事件发生率更高,疾病进展速度更快,预后更差。本文就PBC-AIH重叠综合征的诊治进展作一综述,以期提高临床医师对该病的认识。

关键词: 肝炎,自身免疫性, 胆管炎, 诊断, 治疗

中图分类号:

R575.1

游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2024.01.016

https://lchc.magtechjournal.com/CN/Y2024/V39/I1/84

参考文献 38

[1]	Montano-Loza AJ, Allegretti JR, Cheung A, et al. Single topic conference on autoimmune liver disease from the Canadian Association for the study of the liver[J]. Can Liver J, 2021, 4(4): 401-425. doi: 10.3138/canlivj-2021-0006 URL
[2]	The Committee of the Autoantibodies Detection of Rheumatology and Immunology Physicians Committee of Chinese Medical Doctor Association. Expert consensus on clinical application of autoantibodies detection in patients with autoimmune liver disease[J]. Chin J Intern Med, 2021, 60(7): 619-625.
[3]	中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 中华肝脏病杂志, 2022, 30(3): 264-275.
[4]	Schulz L, Sebode M, Weidemann SA, et al. Variant syndromes of primary biliary cholangitis[J]. Best Pract Res Clin Gastroenterol, 2018, 34-35:55-61. doi: S1521-6918(18)30027-1 pmid: 30343711
[5]	Li Z, Liu Y, Yang F, et al. Dysregulation of circulating FGF19 and bile acids in primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Biomed Res Int, 2020, 2020:1934541.
[6]	To U, Silveira M. Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 603-611. doi: S1089-3261(18)30035-7 pmid: 30259856
[7]	Yan YL, Xing X, Wang Y, et al. Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome[J]. World J Gastroenterol, 2022, 28(18): 2021-2033. doi: 10.3748/wjg.v28.i18.2021 URL
[8]	European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. doi: S0168-8278(17)30186-1 pmid: 28427765
[9]	Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy[J]. Hepatology, 1998, 28(2):296-301. doi: 10.1002/hep.510280203 pmid: 9695990
[10]	倪萍, 凡小丽, 杨丽. 自身免疫性肝病重叠综合征的研究现状[J]. 临床肝胆病杂志, 2020, 36(4): 743-748.
[11]	Kuiper EM, Zondervan PE, Van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome[J]. Clin Gastroenterol Hepatol, 2010, 8(6): 530-534. doi: 10.1016/j.cgh.2010.03.004 URL
[12]	Liu F, Pan ZG, Ye J, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Simplified criteria may be effective in the diagnosis in Chinese patients[J]. J Dig Dis, 2014, 15(12): 660-668. doi: 10.1111/cdd.2014.15.issue-12 URL
[13]	张骏飞, 许何明, 宋海燕, 等. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征:巴黎标准诊断中国患者灵敏度低[J]. 实用肝脏病杂志, 2019, 22(4): 537-540.
[14]	杨宁, 刘雁声, 韩英. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治[J]. 临床肝胆病杂志, 2020, 36(3): 697-700.
[15]	Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. doi: 10.1016/j.jhep.2010.09.002 pmid: 21067838
[16]	Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5):929-538. doi: 10.1016/s0168-8278(99)80297-9 pmid: 10580593
[17]	Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. doi: 10.1002/hep.22322 pmid: 18537184
[18]	Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: A simplified scoring system may assist in the diagnosis[J]. Am J Gastroenterol, 2010, 105(2): 345-353. doi: 10.1038/ajg.2009.616 pmid: 19888204
[19]	Zhang W, De D, Mohammed KA, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Hepatol Commun, 2018, 2(3): 245-253. doi: 10.1002/hep4.1148 pmid: 29507900
[20]	Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365. doi: S0168-8278(19)30228-4 pmid: 30980847
[21]	Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115(2): 262-270. doi: 10.14309/ajg.0000000000000512 pmid: 31985529
[22]	中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华肝脏病杂志, 2022, 30(5): 482-492.
[23]	Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis, 2019, 20(7): 331-337. doi: 10.1111/cdd.2019.20.issue-7 URL
[24]	王绮夏, 马雄. 自身免疫性肝病重叠综合征诊治进展[J]. 胃肠病学, 2018, 23(5): 283-286.
[25]	张晓梅. 熊去氧胆酸单药治疗原发性胆汁性肝硬化肝炎重叠综合征的临床研究[J]. 现代消化及介入诊疗, 2017, 22(4): 487-489.
[26]	郭丽萍, 周璐, 李树倩, 等. 熊去氧胆酸单药或联合免疫抑制剂治疗原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征的疗效分析[J]. 中华消化杂志, 2016, 36(3): 155-160.
[27]	Chazouillères O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406. doi: 10.1016/j.jhep.2005.10.017 pmid: 16356577
[28]	Ozaslan E, Efe C, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2014, 12(5): 863-869. doi: 10.1016/j.cgh.2013.09.021 URL
[29]	Fan X, Zhu Y, Men R, et al. Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: A real-world study[J]. Can J Gastroenterol Hepatol, 2018, 2018: 1965492.
[30]	Freedman BL, Danford CJ, Patwardhan V, et al. Treatment of overlap syndromes in autoimmune liver disease: A systematic review and meta-analysis[J]. J Clin Med, 2020, 9(5): 1449.
[31]	Baven-Pronk AM, Coenraad MJ, Van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes[J]. Aliment Pharmacol Ther, 2011, 34(3): 335-343. doi: 10.1111/apt.2011.34.issue-3 URL
[32]	Efe C, Hagström H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15(12): 1950-1956. doi: 10.1016/j.cgh.2017.06.001 URL
[33]	Hanouneh M, Ritchie MM, Ascha M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol, 2019, 54(1): 76-80. doi: 10.1080/00365521.2018.1551498 URL
[34]	Faisal N, Renner EL. Recurrence of autoimmune liver diseases after liver transplantation[J]. World J Hepatol, 2015, 7(29): 2896-2905. doi: 10.4254/wjh.v7.i29.2896 pmid: 26689244
[35]	Liberal R, Zen Y, Mieli-Vergani G, et al. Liver transplantation and autoimmune liver diseases[J]. Liver Transpl, 2013, 19(10): 1065-1077. doi: 10.1002/lt.v19.10 URL
[36]	Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes[J]. Am J Gastroenterol, 2007, 102(6): 1244-1250. pmid: 17319931
[37]	Park Y, Cho Y, Cho EJ, et al. Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: Characteristics, treatments, and outcomes[J]. Clin Mol Hepatol, 2015, 21(2): 150-157. doi: 10.3350/cmh.2015.21.2.150 pmid: 26157752
[38]	Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2016, 50(1): 114-123. doi: 10.1007/s12016-015-8516-5 URL

原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵世亮, 牛艳国, 赵燕民, 李俊青, 洪丽, 王献. 颅内动脉瘤介入术后认知功能障碍的因素探讨:基于PSM法[J]. 临床荟萃, 2025, 40(4): 320-324.
[2]	苏淼, 王飒爽, 赵东强. 《中国肥胖症消化内镜治疗专家共识》解读[J]. 临床荟萃, 2025, 40(4): 366-371.
[3]	蒲武涛, 肖宜欣, 妥丽, 凯丽比努尔·马木提, 范雪婷, 崇乐. 超声造影诊断肝包虫病的系统评价和meta分析[J]. 临床荟萃, 2025, 40(3): 197-204.
[4]	黄兴舟, 郑卫华, 张树桐, 陈燕浩. 载药微球与常规支气管动脉化疗栓塞术治疗晚期非小细胞肺癌的临床疗效及安全性对比[J]. 临床荟萃, 2025, 40(3): 243-250.
[5]	李忠标, 赵习浩, 杜敏, 王江, 于跃, 张佃良. 肠腔内生性卵巢外腹膜浆液性乳头状腺癌1例并文献复习[J]. 临床荟萃, 2025, 40(3): 257-261.
[6]	季万里, 马周, 石郁喜, 孙为生. 青年脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2025, 40(3): 262-265.
[7]	陈诚, 钱卓宇, 全栩毅, 段圣武. 结直肠癌浆膜及肌层受累影像诊断的研究进展[J]. 临床荟萃, 2025, 40(3): 281-284.
[8]	叶倩, 刘申香. D-二聚体与接受PD-1/PD-L1抑制剂治疗的晚期肿瘤患者长期预后的关系:一项Meta分析[J]. 临床荟萃, 2025, 40(2): 101-106.
[9]	吴万锋, 王云云, 杨道坤. 新型冠状病毒感染应用不同抗病毒药物治疗后的疗效分析[J]. 临床荟萃, 2025, 40(2): 147-152.
[10]	申帅洁, 陈荣梯, 朱嵩, 平芬. 乳酸脱氢酶在难治性肺炎支原体肺炎中的临床应用进展[J]. 临床荟萃, 2025, 40(2): 185-188.
[11]	字颖, 施雨辰, 施荣杰. 淋巴管平滑肌瘤病研究进展[J]. 临床荟萃, 2025, 40(2): 189-192.
[12]	周智明, 茹意, 李萍, 平芬. 多光谱照射联合常规治疗在慢性阻塞性肺疾病急性加重期患者中的临床应用[J]. 临床荟萃, 2025, 40(1): 27-32.
[13]	张迎秋, 张津, 葛世豪, 陈俊敏. 成人DWI脑皮质“花边征”1例并文献复习[J]. 临床荟萃, 2024, 39(9): 821-824.
[14]	散丹, 甄瑾. 脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2024, 39(9): 825-827.
[15]	高胜男, 张冉冉, 张羽曦, 高宁, 冯冰, 刘国强. 我国糖尿病神经病理性疼痛疾病负担及药物治疗进展[J]. 临床荟萃, 2024, 39(9): 842-846.